Information Provided By:
Fly News Breaks for December 17, 2018
NUVA
Dec 17, 2018 | 18:17 EDT
Credit Suisse analyst Matt Miksic initiated NuVasive with an Outperform rating and a price target of $66 as part of his broader research note on Medical Supplies and Devices partially titled "No Disruption, No Alpha". The analyst calls the company an "innovative and disruptive force in MIS spine surgery" as it recovers from a challenging second-half of 2017 and Q1 of 2018. Miksic adds that the new NuVasive CEO should "positively affect the business, given his extensive commercial experience from large-scale operations and growth businesses".
News For NUVA From the Last 2 Days
There are no results for your query NUVA